values are 3.3, 32 and 2000 nM for PPARγ
respectively). Blocks the inhibition of osteoclast formation induced by IL-4 in the low micromolar range (1-2 μ
M), therefore is more potent than BADGE
(Cat. No. 1326). Anticancer, inhibits growth of human mammary tumor cell lines.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor γ1.
Bendixen et al.
Functional consequences of cysteine modification in the ligand binding sites of peroxisone proliferator activated receptors by GW9662.
Leesnitzer et al.
GW9662, a potent antaognist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation.
Seargent et al.
The citations listed below are publications that use Tocris products. Selected citations for GW 9662 include:
Showing Results 1 - 6 of 6